HOME >> MEDICINE >> NEWS
Newest version of 'the pill' confers same stroke risk as old pill

SAN ANTONIO, Feb. 7 The first major study of ischemic stroke in women taking the latest form of low-estrogen birth control pills finds that they still have about double the stroke risk of women not taking the pill. These findings were reported today at the American Stroke Associations 27th International Stroke Conference. The American Stroke Association is a division of the American Heart Association.

In absolute terms, the number of women likely to have stroke from taking the pill rises from about three women to six per 10,000 a year, say the Dutch researchers.

Ischemic stroke is caused by insufficient blood flow to the brain, most commonly due to a blood clot that blocks circulation.

Oral contraceptives (OCs) are a mixture of synthetic female hormones. First-generation birth control pills, introduced in the 1960s, contained very high doses of estrogens and the progestogens lynestrenol or norethisterone. These pills were associated with an increased risk of blood clots, known as thrombotic events. Blood clots can travel to the heart, causing a heart attack, or to the brain, causing a stroke.

In the early 1970s, second-generation birth control pills were developed with the intent to reduce thrombotic events. They contain low estrogen (less than 50 micrograms) and the progestogen levonorgestrel.

A decade later, third-generation OCs were developed to try to decrease side effects associated with the progestogens in the second-generation preparations such as weight gain, acne and adverse changes in cholesterol levels. Third-generation formulations also contained less estrogen than first generation but combined them with different progestogens: desogestrel or gestodene.

Previous studies of second-generation OCs found an increased stroke risk particularly among smokers and women with high blood pressure. There is limited data on third-generation pills. In the current study, researchers assessed the risk of ischemic strok
'"/>

Contact: Carole Bullock or Bridgette McNeill
210-582-7159
American Heart Association
7-Feb-2002


Page: 1 2 3

Related medicine news :

1. Newest Depression Medications Widely Prescribed For Children
2. Supporters of NIH policy see publishers gambit as possible diversion
3. Camera pill promising for diagnosis of small bowel disease
4. Virtual stomach reveals pills path
5. GSA confers 2004 Nathan Shock New Investigator Award to UTHSCs Marciniak
6. The Gerontological Society of America confers 2004 M. Powell Lawton Award to Penn States Zarit
7. GSA confers 2004 Joseph T. Freeman Award to St. Louis Universitys Morley
8. GSA confers 2004 Distinguished Mentorship in Gerontology Award to the Michigans Jackson
9. GSA confers 2004 Richard Kalish Innovative Publication Award to W. Ontarios Connidis and McMullin
10. The Gerontological Society of America confers 2003 Kalish Award to Utahs Pasupathi
11. The Gerontological Society of America confers 2003 Lawton Award to Columbia Universitys Gurland

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Newest version the pill confers same stroke risk old pill

(Date:5/18/2013)... In a May 14, 2013 article entitled “Angelina Jolie ... Gene,” Fox News reported the movie star had opted ... a gene that doctors estimated gave her an 87 ... risk of ovarian cancer (go to: goo.gl/5JHBP). Ms. Jolie’s ... a blog post entitled “A Patient’s Journey: Angelina Jolie” ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Today, ... insurance agents’ role in Marketplaces . Zane ... traditional employer sponsored health benefits, is the leader ... and health reimbursement arrangements . , According ... and Human Services (HHS) recently released a much-anticipated ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- It ... but new research shows that college women are more likely ... than are college men. Much of this difference ... on a weekly basis is much lower for women than ... for men. But, there,s good reason for that difference. Women ...
(Date:5/18/2013)... 2013 TheBeautyPlace.com answers important questions about ... is not a result of stress, nutrient deficiency or ... Magazine, 70% of men suffer from male patterned baldness. ... renowned for hair transplant surgery, but additionally carries a ... known as Bosley Professional Strength. Their product line is ...
(Date:5/18/2013)... May 18, 2013 During Better Hearing ... should consider the legal protections they have, including the ... arise with their child’s treatment or hearing aid device, ... 1927, the American Speech-Language-Hearing Association has used the month ... to promote treatment, such as cochlear implants, which can ...
Breaking Medicine News(10 mins):Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3
(Date:5/17/2013)... 17, 2013  TechAtlas Group has announced the ... landscape map for the Chronic Kidney Disease (CKD) ... companies with drugs and devices currently on the ... sequelae. (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ... hypertension - renal denervation , diabetic nephropathy ...
(Date:5/17/2013)... 17, 2013 Fuse Science, Inc. (OTCQB: DROP), ( ... is developing new, patent-pending technologies poised to redefine how consumers ... will hold a business update teleconference and webcast for shareholders ... 2013 at 4:30 PM ET. Fuse Science, ... the call and will be joined by Rubin ...
(Date:5/17/2013)... 2013  Sanofi (EURONEXT: SAN and NYSE: SNY ... JAKARTA , examining the selective JAK2 inhibitor SAR302503 ... dose groups. The primary endpoint assessed the proportion of ... data reported in previous trials, the most common adverse ... will be presented at an upcoming medical congress. ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
Cached News: